331 related articles for article (PubMed ID: 35567547)
21. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
[TBL] [Abstract][Full Text] [Related]
22. A modified immune cell infiltration score achieves ideal stratification for CD8
Pan B; Luo Y; Ye D; Qiu J; Zhang X; Wu X; Yao Y; Wang X; Tang N
Cancer Immunol Immunother; 2023 Dec; 72(12):4103-4119. PubMed ID: 37755466
[TBL] [Abstract][Full Text] [Related]
23. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
Chen S; Huang C; Liao G; Sun H; Xie Y; Liao C; Wang J; He M; Hu H; Dai Z; Ren X; Zeng X; Lin Z; Zhang GP; Xie W; Shen S; Li S; Peng S; Kuang DM; Zhao Q; Duda DG; Kuang M
Gut; 2023 Jun; 72(6):1196-1210. PubMed ID: 36596711
[TBL] [Abstract][Full Text] [Related]
24. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.
Chen L; Zhou Q; Liu J; Zhang W
Front Immunol; 2021; 12():759565. PubMed ID: 34777372
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.
Zhang F; Liu W; Meng F; Jiang Q; Tang W; Liu Z; Lin X; Xue R; Zhang S; Dong L
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272562
[TBL] [Abstract][Full Text] [Related]
26. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
27. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
28. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration.
Jiang Y; Chen S; Li Q; Liang J; Lin W; Li J; Liu Z; Wen M; Cao M; Hong J
Front Immunol; 2021; 12():612139. PubMed ID: 33679751
[TBL] [Abstract][Full Text] [Related]
29. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
30. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
Zhang G
Front Immunol; 2022; 13():975762. PubMed ID: 36189226
[TBL] [Abstract][Full Text] [Related]
31. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.
Liu X; Zhou J; Wu H; Chen S; Zhang L; Tang W; Duan L; Wang Y; McCabe E; Hu M; Yu Z; Liu H; Choi CHJ; Sung JJ; Huang L; Liu R; Cheng AS
Mol Ther; 2023 Jan; 31(1):119-133. PubMed ID: 36146933
[TBL] [Abstract][Full Text] [Related]
32. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Sasaki T; Shigeta K; Kitahara S; Suzuki Y; Matsui S; Seishima R; Okabayashi K; Duda DG; Kitagawa Y
Anticancer Res; 2022 Nov; 42(11):5205-5215. PubMed ID: 36288859
[TBL] [Abstract][Full Text] [Related]
34. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
35. A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.
Su X; Yin H; Bai M; Liu J; Liu R; Zeng H; Wen J
J Immunol; 2023 Mar; 210(5):681-695. PubMed ID: 36602827
[TBL] [Abstract][Full Text] [Related]
36. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
[TBL] [Abstract][Full Text] [Related]
37. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
[TBL] [Abstract][Full Text] [Related]
38. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
39. CD38 marks the exhausted CD8
Reolo MJY; Otsuka M; Seow JJW; Lee J; Lee YH; Nguyen PHD; Lim CJ; Wasser M; Chua C; Lim TKH; Leow WQ; Chung A; Goh BKP; Chow PKH; DasGupta R; Yeong JPS; Chew V
Front Immunol; 2023; 14():1182016. PubMed ID: 37377962
[TBL] [Abstract][Full Text] [Related]
40. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]